Fortress Biotech Inc
NASDAQ:FBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shenzhen Sunlord Electronics Co Ltd
SZSE:002138
|
CN |
Fortress Biotech Inc
Total Current Assets
Fortress Biotech Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
Total Current Assets
$118.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Fortress Biotech Inc
Glance View
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 173 full-time employees. The company went IPO on 2011-11-17. Fortress has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, and at its partner companies. Its product candidates span six market areas, including oncology, rare diseases and gene therapy. The firm's commercialized products include Ximino, Targadox, Exelderm, Ceracade, Luxamend and Accutane. Its late-stage product candidates include Intravenous (IV) Tramadol, CUTX-101, MB-107 and MB-207, Cosibelimab, CK-101, CAEL-101, Triplex and CEVA101. Its product candidates also consist of MB-102 (CD123 CAR T for BPDCN), MB-101 (IL13Ra2 CAR T for Glioblastoma), MB-104, MB-106, MB-103, AVTS-001, CK-103 and ConVax. The firm operates in two operating and reportable segments: Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
See Also
What is Fortress Biotech Inc's Total Current Assets?
Total Current Assets
118.5m
USD
Based on the financial report for Sep 30, 2025, Fortress Biotech Inc's Total Current Assets amounts to 118.5m USD.
What is Fortress Biotech Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
6%
Over the last year, the Total Current Assets growth was 37%. The average annual Total Current Assets growth rates for Fortress Biotech Inc have been -23% over the past three years , -13% over the past five years , and 6% over the past ten years .
